Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oremepermin alfa - Claris Biotherapeutics/Kringle Pharma

Next Previous
Drug Profile

Oremepermin alfa - Claris Biotherapeutics/Kringle Pharma

Alternative Names: CSB-001; Hepatocyte growth factor - Kringle Pharma; KP-100 - Kringle Pharma; KP-100IT; KP-100LI

Latest Information Update: 06 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kringle Pharma
  • Developer Claris Biotherapeutics; Kringle Pharma
  • Class Eye disorder therapies; Growth factors; Recombinant proteins
  • Mechanism of Action Hepatocyte growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Scars; Spinal cord injuries
  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Neurotrophic keratopathy
  • Phase I Acute kidney injury; Corneal injuries; Limbal stem cell deficiency

Most Recent Events

  • 06 Aug 2026 Oremepermin alfa is still in phase I trial for Acute kidney injury in USA (Kringle Pharma pipeline, August 2026)
  • 28 Jul 2026 Efficacy and adverse events data from a phase III trial in Spinal cord injuries released by Kringle Pharma
  • 28 Jul 2026 Claris Biotherapeutics plans two pivotal clinical trials for Limbal stem cell deficiency in first half of 2027 (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top